FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

[GlobeNewswire] – CHICAGO — Durata Therapeutics, Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Anti-Infective Drugs Advisory Committee voted 12 to 0 that the Company has provided substantial evidence … more

View todays social media effects on DRTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Durata is hiring next, click here to view